#USA #Chicago #Lupus Research Alliance #ACR Convergence #Lupus Therapeutics

The Lupus Research Alliance at ACR Convergence 2025

The upcoming ACR Convergence 2025, taking place from October 24 to 29 in Chicago, will serve as a pivotal platform for the Lupus Research Alliance (LRA). This gathering, organized by the American College of Rheumatology, will see LRA present its extensive research efforts aimed at shaping future lupus therapies. With more than 650 research grants and a significant presence in ongoing clinical trials, LRA continues to push towards breakthroughs in lupus treatment.

Accelerating Advances in Lupus Research

Lupus is a complex autoimmune disease impacting millions, primarily affecting women of childbearing age. The LRA stands as the world’s largest private funder for lupus research, significantly investing in both basic and translational research, and driving the potential approval of new therapies. Albert T. Roy, the organization’s President and CEO, expressed optimism, stating, "With only a handful of therapies ever approved for lupus, the next wave of breakthroughs could redefine treatment for millions worldwide – and we're right at that precipice."

At the ACR Convergence, four original posters will highlight critical findings from innovative programs such as the Lupus Accelerating Breakthroughs Consortium and Lupus Nexus. The aim is to illustrate enhanced strategies for patient recruitment and retention in clinical trials, particularly through patient-reported outcomes, which emphasize the experiences of those living with lupus.

Key Presentations and Findings

The following key abstracts will be presented:

1. Abstract 0377: Focuses on incorporating patient-reported outcomes into clinical trial protocols to ensure relevance to those directly impacted by the disease.
2. Abstract 2561: Examines how strategies centered on patient engagement can boost both recruitment and retention in the Lupus Landmark Study, a pioneering longitudinal study designed to track the health of approximately 3,500 adults with lupus.
3. Abstract 0652: Evaluates how clinical trial sites can prepare for engineered cell therapies in lupus, a revolutionary approach with the potential to change treatment paradigms.
4. Abstract 1915: Discusses innovative recruitment techniques utilizing social media and AI to engage more effectively with potential participants.

These presentations aim to illuminate a significant shift in research methodologies, revealing both challenges and promising opportunities for lupus therapy innovations.

Celebration of Lupus Innovation

Not only will LRA feature its research at ACR Convergence, but the organization also plans to host a community reception. This gathering will focus on celebrating collaboration among researchers, clinical practitioners, and lupus warriors, along with recognizing outstanding contributions to the field through inaugural awards, such as:

• - Lupus Research Alliance Research Visionary Award
• - Lupus Research Alliance Research Champion Award
• - Lupus Therapeutics Impact Award
• - Excellence in Patient Engagement in Lupus Clinical Trials

Dr. Roberto Caricchio, Vice Chair of the Lupus Clinical Investigators Network (LuCIN), remarked, “We are at the peak of innovation in lupus,” emphasizing the urgency of translating research advances into practical treatments that improve the quality of life for those suffering from the disease.

Future Aspirations for Lupus Research

As the LRA prepares for the ACR Convergence 2025, its representatives stress the necessity of bold, innovative, and collaborative research approaches to foster advancements that directly benefit the lupus community. They aim to ensure that ongoing research translates into tangible outcomes that improve patient lives, reduce disease progression, and minimize treatment side effects.

The LRA invites everyone interested in lupus advancements to visit them at Booth #2225 at McCormick Center during the conference. Visitors can learn more about their projects and discover how they can contribute to the fight against lupus.

In conclusion, the drive for innovative and effective lupus treatments is at an inflection point, with organizations like the Lupus Research Alliance leading the way. With the scholarly work being showcased at ACR Convergence 2025, the future of lupus research looks promising, filled with hope for patients and their families.